ZYESAMI

aviptadil acetate · APR Applied Pharma Research s.a.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ZYESAMI, covering 2023-02-03 to 2023-02-03. Get the full timeline:

Most recent: Clinical Trial Update: Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19 [Phase 2, Phase 3]